APO RESEARCH · REPORT
Onychomycosis (Tinea Unguium) Drug
Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate.
Product & engineering
Understand the product.
Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate.
Onychomycosis (Tinea Unguium) Drug is the drug for the treatment of the disease.
Selected research
Industry Research
Onychomycosis (Tinea Unguium) Drug Industry Research Report 2026
Market perspective
Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate.
Onychomycosis (Tinea Unguium) Drug is the drug for the treatment of the disease.
Global Onychomycosis (Tinea Unguium) Drug key players include Pfizer, J&J, Novartis, Galderma pharm, Valeant Pharma, etc. Global top five manufacturers hold a share about 35%.
Read the full market overview
North America is the largest market, with a share about 30%, followed by Europe and China both have a share over 45 percent.
In terms of product, Oral Medication is the largest segment, with a share over 70%. And in terms of application, the largest application is Age above 50, followed by Age under 18.
Report Scope
This report quantifies the global Onychomycosis (Tinea Unguium) Drug market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Onychomycosis (Tinea Unguium) Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Onychomycosis (Tinea Unguium) Drug Market by Company
Pfizer
Yangtze River
Torrent Pharma
J&J
Chengdu Brilliant
Novartis
Qilu Pharmaceutical
Xiuzheng Pharmaceutical
Hubei Hengan
TARO
Perrigo
Galderma pharm
Zhejiang Deyer
Valeant Pharma
Moberg
Onychomycosis (Tinea Unguium) Drug Segment by Type
Oral Medication
External Medicine
Onychomycosis (Tinea Unguium) Drug Segment by Application
Age under 18
Age 18-50
Age above 50
Onychomycosis (Tinea Unguium) Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Onychomycosis (Tinea Unguium) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Onychomycosis (Tinea Unguium) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Onychomycosis (Tinea Unguium) Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Onychomycosis (Tinea Unguium) Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral Medication
- External Medicine
Applications
- Age under 18
- Age 18-50
- Age above 50
Companies covered
- Pfizer
- Yangtze River
- Torrent Pharma
- J&J
- Chengdu Brilliant
- Novartis
- Qilu Pharmaceutical
- Xiuzheng Pharmaceutical
- Hubei Hengan
- TARO
- Perrigo
- Galderma pharm
- Zhejiang Deyer
- Valeant Pharma
- Moberg
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Onychomycosis (Tinea Unguium) Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Oral Medication
- 2.2.3 External Medicine
- 2.3 Onychomycosis (Tinea Unguium) Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Age under 18
- 2.3.3 Age 18-50
- 2.3.4 Age above 50
- 2.4 Assumptions and Limitations
3 Onychomycosis (Tinea Unguium) Drug Breakdown Data by Type
- 3.1 Global Onychomycosis (Tinea Unguium) Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Onychomycosis (Tinea Unguium) Drug Forecasted Market Size by Type (2027-2032)
4 Onychomycosis (Tinea Unguium) Drug Breakdown Data by Application
- 4.1 Global Onychomycosis (Tinea Unguium) Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Onychomycosis (Tinea Unguium) Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Onychomycosis (Tinea Unguium) Drug Market Perspective (2021-2032)
- 5.2 Global Onychomycosis (Tinea Unguium) Drug Growth Trends by Region
- 5.2.1 Global Onychomycosis (Tinea Unguium) Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Onychomycosis (Tinea Unguium) Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Onychomycosis (Tinea Unguium) Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Onychomycosis (Tinea Unguium) Drug Market Dynamics
- 5.3.1 Onychomycosis (Tinea Unguium) Drug Industry Trends
- 5.3.2 Onychomycosis (Tinea Unguium) Drug Market Drivers
- 5.3.3 Onychomycosis (Tinea Unguium) Drug Market Challenges
- 5.3.4 Onychomycosis (Tinea Unguium) Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Onychomycosis (Tinea Unguium) Drug Players by Revenue
- 6.1.1 Global Top Onychomycosis (Tinea Unguium) Drug Players by Revenue (2021-2026)
- 6.1.2 Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Onychomycosis (Tinea Unguium) Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Onychomycosis (Tinea Unguium) Drug Head Office and Area Served
- 6.4 Global Onychomycosis (Tinea Unguium) Drug Players, Product Type & Application
- 6.5 Global Onychomycosis (Tinea Unguium) Drug Manufacturers Established Date
- 6.6 Global Onychomycosis (Tinea Unguium) Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Onychomycosis (Tinea Unguium) Drug Market Size (2021-2032)
- 7.2 North America Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2021-2026)
- 7.4 North America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Onychomycosis (Tinea Unguium) Drug Market Size (2021-2032)
- 8.2 Europe Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Onychomycosis (Tinea Unguium) Drug Market Size by Country (2021-2026)
- 8.4 Europe Onychomycosis (Tinea Unguium) Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Onychomycosis (Tinea Unguium) Drug Market Size (2021-2032)
- 10.2 South America Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2021-2026)
- 10.4 South America Onychomycosis (Tinea Unguium) Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Pfizer
- 12.1.1 Pfizer Company Information
- 12.1.2 Pfizer Business Overview
- 12.1.3 Pfizer Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021-2026)
- 12.1.4 Pfizer Onychomycosis (Tinea Unguium) Drug Product Portfolio
- 12.1.5 Pfizer Recent Developments
- 12.2 Yangtze River
- 12.2.1 Yangtze River Company Information
- 12.2.2 Yangtze River Business Overview
- 12.2.3 Yangtze River Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021-2026)
- 12.2.4 Yangtze River Onychomycosis (Tinea Unguium) Drug Product Portfolio
- 12.2.5 Yangtze River Recent Developments
- 12.3 Torrent Pharma
- 12.3.1 Torrent Pharma Company Information
- 12.3.2 Torrent Pharma Business Overview
- 12.3.3 Torrent Pharma Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021-2026)
- 12.3.4 Torrent Pharma Onychomycosis (Tinea Unguium) Drug Product Portfolio
- 12.3.5 Torrent Pharma Recent Developments
- 12.4 J&J
- 12.4.1 J&J Company Information
- 12.4.2 J&J Business Overview
- 12.4.3 J&J Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021-2026)
- 12.4.4 J&J Onychomycosis (Tinea Unguium) Drug Product Portfolio
- 12.4.5 J&J Recent Developments
- 12.5 Chengdu Brilliant
- 12.5.1 Chengdu Brilliant Company Information
- 12.5.2 Chengdu Brilliant Business Overview
- 12.5.3 Chengdu Brilliant Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021-2026)
- 12.5.4 Chengdu Brilliant Onychomycosis (Tinea Unguium) Drug Product Portfolio
- 12.5.5 Chengdu Brilliant Recent Developments
- 12.6 Novartis
- 12.6.1 Novartis Company Information
- 12.6.2 Novartis Business Overview
- 12.6.3 Novartis Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021-2026)
- 12.6.4 Novartis Onychomycosis (Tinea Unguium) Drug Product Portfolio
- 12.6.5 Novartis Recent Developments
- 12.7 Qilu Pharmaceutical
- 12.7.1 Qilu Pharmaceutical Company Information
- 12.7.2 Qilu Pharmaceutical Business Overview
- 12.7.3 Qilu Pharmaceutical Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021-2026)
- 12.7.4 Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Product Portfolio
- 12.7.5 Qilu Pharmaceutical Recent Developments
- 12.8 Xiuzheng Pharmaceutical
- 12.8.1 Xiuzheng Pharmaceutical Company Information
- 12.8.2 Xiuzheng Pharmaceutical Business Overview
- 12.8.3 Xiuzheng Pharmaceutical Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021-2026)
- 12.8.4 Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Product Portfolio
- 12.8.5 Xiuzheng Pharmaceutical Recent Developments
- 12.9 Hubei Hengan
- 12.9.1 Hubei Hengan Company Information
- 12.9.2 Hubei Hengan Business Overview
- 12.9.3 Hubei Hengan Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021-2026)
- 12.9.4 Hubei Hengan Onychomycosis (Tinea Unguium) Drug Product Portfolio
- 12.9.5 Hubei Hengan Recent Developments
- 12.10 TARO
- 12.10.1 TARO Company Information
- 12.10.2 TARO Business Overview
- 12.10.3 TARO Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021-2026)
- 12.10.4 TARO Onychomycosis (Tinea Unguium) Drug Product Portfolio
- 12.10.5 TARO Recent Developments
- 12.11 Perrigo
- 12.11.1 Perrigo Company Information
- 12.11.2 Perrigo Business Overview
- 12.11.3 Perrigo Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021-2026)
- 12.11.4 Perrigo Onychomycosis (Tinea Unguium) Drug Product Portfolio
- 12.11.5 Perrigo Recent Developments
- 12.12 Galderma pharm
- 12.12.1 Galderma pharm Company Information
- 12.12.2 Galderma pharm Business Overview
- 12.12.3 Galderma pharm Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021-2026)
- 12.12.4 Galderma pharm Onychomycosis (Tinea Unguium) Drug Product Portfolio
- 12.12.5 Galderma pharm Recent Developments
- 12.13 Zhejiang Deyer
- 12.13.1 Zhejiang Deyer Company Information
- 12.13.2 Zhejiang Deyer Business Overview
- 12.13.3 Zhejiang Deyer Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021-2026)
- 12.13.4 Zhejiang Deyer Onychomycosis (Tinea Unguium) Drug Product Portfolio
- 12.13.5 Zhejiang Deyer Recent Developments
- 12.14 Valeant Pharma
- 12.14.1 Valeant Pharma Company Information
- 12.14.2 Valeant Pharma Business Overview
- 12.14.3 Valeant Pharma Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021-2026)
- 12.14.4 Valeant Pharma Onychomycosis (Tinea Unguium) Drug Product Portfolio
- 12.14.5 Valeant Pharma Recent Developments
- 12.15 Moberg
- 12.15.1 Moberg Company Information
- 12.15.2 Moberg Business Overview
- 12.15.3 Moberg Revenue in Onychomycosis (Tinea Unguium) Drug Business (2021-2026)
- 12.15.4 Moberg Onychomycosis (Tinea Unguium) Drug Product Portfolio
- 12.15.5 Moberg Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst